

Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response

Unsun Lee, Ludmila Szabova, Victor J. Collins, Melanie Gordon, Kristine Johnson, Deborah Householder, Stephanie Jorgensen, Lucy Lu, Laura Bassel, Fathi Elloumi, Cody J. Peer, Ariana E. Nelson, Sophia Varriano, Sudhir Varma, Ryan D. Roberts, Zoe Weaver Ohler, William D. Figg, Shyam K. Sharan, Yves Pommier, Christine M. Heske

Supplemental Table S4. Molecular characteristics of EWS cell lines. (1, 2)

| Cell Line | Fusion Type      | TP53                      | STAG2              |
|-----------|------------------|---------------------------|--------------------|
| EW8       | EWS-FLI1 Type I  | Y220C- No protein         | N475fs- No protein |
| TC71      | EWS-FLI1 Type I  | R213X & G245C- No protein |                    |
| TC32      | EWS-FLI1 Type I  |                           | Y636fs- No protein |
| RDES      | EWS-FLI1 Type II | R273C                     |                    |
| 5838      | EWS-ERG          | Unknown                   | Unknown            |
| ES1       | EWS-FLI1 Type II | R248Q                     |                    |
| ES4       | EWS-FLI1 Type II |                           |                    |
| ES6       | EWS-FLI1 (9/4)   | Expression loss           | L264P              |

1. Brohl, A.S., et al., *The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation*. PLoS Genet, 2014. **10**(7): p. e1004475.  
2. Dunn, T., L. Praissman, N. Hagag, and M.V. Viola, *ERG gene is translocated in an Ewing's sarcoma cell line*. Cancer Genet Cytogenet, 1994. **76**(1): p. 19-22.